Lexicon Pharmaceuticals (LXRX)
Lexicon Pharmaceuticals R&D Expense: 23.04M
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Select a metric
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
LXRX R&D Expense Rankings
| Overall | 19th percentile | 1412 of 1763 |
| Sector | 19th percentile | 333 of 413 in Healthcare |
| Industry | 15th percentile | 127 of 151 in Biotechnology |
LXRX R&D Expense Range, Past 5 Years
| Minimum | 18.25M | Dec 2010 |
| Maximum | 30.08M | Jun 2008 |
| Average | 22.89M |
About R&D Expense
R&D expenses are a line item from many companies' income statements.
R&D expense (short for research and development expense) is essentially the amount of money that a company spends to develop new products and services each year. For example, if a pharmaceutical firm hires research scientists to develop new drugs, the salaries of these researchers will generally be expensed in the R&D expense category.
Like marketing expenses, but unlike capital expenditures, R&D expenses are subtracted from revenues every year directly. Therefore, accountants treat R&D spending as an expense rather than as an investment, though there is continuous debate over whether this is the correct classification.
An investor looking at companies with large R&D expenditures should think hard about whether a single company's R&D spending is an expense (like buying rubber to produce tires) or whether it is an investment (like buying machinery to produce tires more efficiently). Determining the answer to that question can have a large impact on how the company is valued.
Learn More
You may also be interested in these LXRX related companies
LXRX News
$LXRX forms bullish "Symmetrical Continuation Triangle" chart pattern. http://stks.co/3rh7
about 13 days ago by RecogniaEvents
about 13 days ago by RecogniaEvents
Lexicon Pharmaceuticals' CEO Discusses Q1 2012 Results - Earnings Call Transcript
May 03, 7:00PM Seeking Alpha
May 03, 7:00PM Seeking Alpha
Listen to $LXRX Q1 2012 earnings call - live at 11:00 AM, ondemand after - http://stks.co/3ePP
about 27 days ago by earningscast
about 27 days ago by earningscast
Lexicon Receives Funding for Phase 2 Clinical Trial of LX4211 in Type 1 Diabetes
May 03, 7:03AM Benzinga
May 03, 7:03AM Benzinga
Lexicon Pharmaceuticals Reports On Clinical Program Status And 2012 First Quarter Results
May 03, 6:00AM PR Newswire
May 03, 6:00AM PR Newswire
Lexicon Pharmaceuticals to Present at the 11th Annual Needham Healthcare Conference
Mar 27, 6:00PM PR Newswire
Mar 27, 6:00PM PR Newswire
FDA Grants Lexicon Orphan Drug Designation for Telotristat Etiprate for the Treatment of Carcinoid Syndrome
Mar 20, 6:00PM PR Newswire
Mar 20, 6:00PM PR Newswire
$LXRX filed latest Proxy Statement with the SEC (Form DEF 14A) http://stks.co/2tlK
about 75 days ago by MarketBrief
about 75 days ago by MarketBrief
Lexicon Pharmaceuticals to Present at the Cowen and Company 32nd Annual Health Care Conference
Feb 29, 6:00PM PR Newswire
Feb 29, 6:00PM PR Newswire
Lexicon Pharmaceuticals' CEO Discusses Q4 2011 Results - Earnings Call Transcript
Feb 22, 5:10PM Seeking Alpha
Feb 22, 5:10PM Seeking Alpha
Lexicon to Report Fourth Quarter and Year End 2011 Financial Results on February 22, 2012
Feb 16, 6:31PM PR Newswire
Feb 16, 6:31PM PR Newswire
@greglaw $lxrx moving averages really don't work on biotech companies. It is all about funding!
about 105 days ago by hedgeflight
about 105 days ago by hedgeflight
@ChimeraResearch $lxrx How can you say it is overvalued? They have 2 drugs that will be in phase 3 later this year. Plus they have cash.
about 105 days ago by hedgeflight
about 105 days ago by hedgeflight
$lxrx add to position as phase 3 trials to begin in late 2012 and diabetes drug has huge potential.
about 105 days ago by hedgeflight
about 105 days ago by hedgeflight
Lexicon Pharmaceuticals to Present at the 14th Annual BIO CEO & Investor Conference
Feb 07, 6:00PM PR Newswire
Feb 07, 6:00PM PR Newswire
Lexicon Pharmaceuticals' CEO Presents at JP Morgan Healthcare Conference (Transcript)
Jan 11, 8:42PM Seeking Alpha
Jan 11, 8:42PM Seeking Alpha
$LXRX http://stks.co/1snv long setup picking up steam.... on the radar
about 140 days ago by stt2318
about 140 days ago by stt2318
Lexicon (LXRX) Says Top-Line Results from LX4211 Study Show Enhanced Effects with DPP-4
Jan 09, 4:41PM Street Insider
Jan 09, 4:41PM Street Insider
LX4211 Enhances Effects of DPP-4 Inhibition in Patients with Type 2 Diabetes
Jan 09, 4:30PM Benzinga
Jan 09, 4:30PM Benzinga
Lexicon Pharmaceuticals to Present at the 30th Annual J.P. Morgan Healthcare Conference
Jan 04, 6:00PM PR Newswire
Jan 04, 6:00PM PR Newswire
Lexicon Pharmaceuticals (LXRX) Completes Offering with Gross Proceeds of $161 Million
Dec 23, 8:31AM Street Insider
Dec 23, 8:31AM Street Insider
FMR LLC Raises Stake in Lexicon Pharmaceuticals, Inc. (LXRX) to 17.55%
Dec 12, 11:43AM Street Insider
Dec 12, 11:43AM Street Insider
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| LXRX | 1.61 | +0.01 | +0.62% | 773.70M |
| LXP | 8.30 | -0.09 | -1.07% | 1.290B |
| LSTR | 54.12 | +0.51 | +0.95% | 2.528B |
| LSI | 6.85 | -0.05 | -0.72% | 3.882B |
| LSG | 0.8744 | -0.02 | -1.75% | 358.71M |
| LSCC | 4.55 | +0.03 | +0.66% | 538.81M |
| LSBK | 9.23 | -0.77 | -7.70% | 54.83M |
| LOOP | 19.17 | +0.00 | +0.00% | 675.55M |
| LOOK | 0.80 | +0.02 | +2.58% | 13.83M |
| LONG | 13.96 | -0.02 | -0.14% | 471.85M |
